Molecular Allergen Immunotherapy (Molecular AIT) is Worg's globally exclusive AIT drug development platform. By identifying the major sensitizing proteins in allergens and achieving high molecular purity, it offers a safer, more effective, and convenient AIT treatment option for allergic disease patients.
Compared to traditional natural extract AIT drugs, molecular AIT products have clear, high-content active ingredients, low side effects, high treatment efficacy, and ease of use.
Worg has already launched 3 molecular AIT products overseas and is actively advancing clinical trials and registration preparations for these products in China.
The sensitization rate for fungal allergens in patients with respiratory allergic diseases worldwide ranges from 3.6% to 12.6%, with children showing a much higher sensitivity to fungi than adults.
Worg's fungal molecular AIT product contains purified major allergens derived from Alternaria species, covering over 90% of patients allergic to fungi.
Cypress pollen sensitization rates reach 4% in patient populations across Europe, North America, and the Middle East. In northern China, around 40% of AR patients are allergic to cypress. Japanese cedar is also one of the most significant allergens in Japan.
Worg's cypress molecular AIT product contains purified major allergens derived from cypress pollen, covering over 94% of patients allergic to cypress.
Dust mites are one of the most common allergens worldwide, with an estimated 130 million people globally allergic to them. In China, over 40% of AR patients are allergic to dust mites.
MOL Mite is the only dust mite AIT product globally that targets three major sensitizing proteins, covering over 90% of allergies caused by dust mites.
Scan
WeChat official account
A wholly-owned subsidiary of Worg PHARMA
